Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Renzapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 7/20 | 0.96 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 4/20 | 0.96 |
| ▸ | HTR3B known ✓ | O95264 | 4/20 | 0.96 |
| ▸ | HTR3D known ✓ | Q70Z44 | 4/20 | 0.96 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 4/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
| ▸ | HTR5A | P47898 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Renzapride SCHEMBL678616 | 0.98 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL4534994 | 0.98 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL17037 | 0.98 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5367707 | 0.97 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5765864 | 0.97 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371909 | 0.97 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371617 | 0.96 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5767174 | 0.96 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8292934 | 0.87 | HTR3A (0.80) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1047947 | 0.86 | HTR3A (0.78) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | HTR3A, HNMT, HTR3B | HTR3A 1/4885HTR3E 6/4885HTR3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.